EDTA

Administration
  • Type: Antidote (chelator)
  • Dosage Forms:
  • Routes of Administration: IV/IM
  • Alternate names: Calcium Disodium Edathamil, Calcium Disodium Edetate, ethylenediamine tetraacetic acid, Edetic acid, Edetate calcium

Adult Dosing
  • Asymptomatic or symptomatic lead poisoning, level 20-70 mcg/dL: 1000 mg/m(2)/day IV over 8-12h OR IM in divided doses q8-12 hours
  • Administer with dimercaprol if level >70 mcg/dL or symptomatic

Pediatric Dosing
  • Same as above

Special Populations
  • Pregnancy Rating: B
  • Lactation risk: Infant risk cannot be ruled out
  • Renal dosing: reduce dose if mild impairment, contraindicated if anuria or active renal disease
  • Hepatic dosing: contraindicated in active hepatitis

Contraindications
  • Allergy to class/drug
  • Anuria, active renal disease
  • Active hepatitis

Adverse Reactions

Serious

All listed here are relatively frequent complications

  • Hypotension
  • Thrombophlebitis
  • Fever
  • Nephrotoxicity
  • Hypersensitivity reaction

Common
  • Injection site pain
  • Nausea/vomiting
  • Myalgia
  • Headache

Pharmacology
  • Half-life: 20-60min
  • Metabolism: Not metabolized
  • Excretion: Renal

Mechanism of Action
  • Divalent/trivalent metals (especially lead) replace calcium in EDTA forming stable, soluble complexes that are readily excreted

Comments

See Also

References
    This article is issued from Wikem. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.